| Date | Title | Description |
| 13.10.2025 | Enzymatica appoints Holger Lembrér as new CFO | Enzymatica appoints Holger Lembrér as new CFO
Mon, Oct 13, 2025 10:00 CET Report this content
Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and w... |
| 06.08.2025 | Swiss stocks decline as officials head to the U.S. to negotiate tariffs | This was CNBC’s live blog covering European markets.
Swiss stocks declined on Wednesday as the country’s President and economic minister were meeting U.S. government officials in an attempt to lower the 39% tariffs imposed by President Trum... |
| 04.11.2024 | Oncopeptides will present at the BioStock Life Science Summit, November 20 | Oncopeptides will present at the BioStock Life Science Summit, November 20
Mon, Nov 04, 2024 11:00 CET Report this content
The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Sofia Heigis w... |
| 12.05.2023 | Oncopeptides presents new data at the European Haematology Association meeting | May 11, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and saf... |
| 04.05.2023 | Oncopeptides publishes Q1 report 2023 | May 4, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes the report for t... |
| 03.05.2023 | Oncopeptides issues warrants to utilize the first loan tranche from EIB | May 3, 2023 Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced that the company... |
| 02.05.2023 | Invitation to presentation of the Q1 report 2023 | May 2, 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on M... |
| 25.04.2023 | Oncopeptides publishes the 2022 Annual Report | April 25, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022... |
| 21.04.2023 | Oncopeptides presents new scientific data at European Myeloma Network Meeting | April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company present... |
| 28.03.2023 | Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors | March 28, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has rece... |
| 10.03.2023 | Oncopeptides CSO released from custody | March 10, 2023
Regulatory
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been informed that th... |
| 08.03.2023 | Oncopeptides CSO investigated for violation of the Market Abuse Act | March 8, 2023
Regulatory
Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för marknadsmiss... |
| 16.02.2023 | Oncopeptides publishes year-end report 2022 | February 16, 2023
Regulatory
Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2022.
Finan... |
| 10.02.2023 | Invitation to presentation of the year-end report 2022 | Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth quarter and the 2022 year-end report, at ... |
| 18.01.2023 | Oncopeptides Chief Financial Officer Holger Lembrer takes office today | Oncopeptides Chief Financial Officer Holger Lembrer takes office today
Wed, Jan 18, 2023 08:00 CET Report this content
STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commerciali... |
| 11.01.2023 | Oncopeptides appoints Holger Lembrer as Chief Financial Officer | STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointe... |
| 11.01.2023 | Oncopeptides appoints Holger Lembrer as Chief Financial Officer | Oncopeptides appoints Holger Lembrer as Chief Financial Officer
Wed, Jan 11, 2023 13:30 CET Report this content
STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and devel... |
| 05.01.2023 | Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer | STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors ha... |
| 04.01.2023 | Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer | Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer
Wed, Jan 04, 2023 09:15 CET Report this content
STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotec... |
| 22.12.2022 | Oncopeptides has announced the Nomination Committee | Oncopeptides has announced the Nomination Committee
Thu, Dec 22, 2022 16:00 CET Report this content
STOCKHOLM — December 22, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomi... |
| 13.12.2022 | Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH |
STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company presents n... |
| 12.12.2022 | Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH | Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH
Mon, Dec 12, 2022 15:00 CET Report this content
STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech co... |
| 07.12.2022 | Oncopeptides provides update on Pepaxto US marketing authorization | STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Admin... |
| 07.12.2022 | Oncopeptides provides update on Pepaxto US marketing authorization | Oncopeptides provides update on Pepaxto US marketing authorization
Wed, Dec 07, 2022 13:45 CET Report this content
STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the deve... |
| 25.11.2022 | Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank | Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank
Fri, Nov 25, 2022 18:00 CET Report this content
STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO... |
| 11.11.2022 | Oncopeptides’ Pepaxti has been granted marketing authorization in the UK | STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti® (melphalan fluf... |
| 11.11.2022 | Oncopeptides’ Pepaxti has been granted marketing authorization in the UK | Oncopeptides’ Pepaxti has been granted marketing authorization in the UK
Fri, Nov 11, 2022 17:15 CET Report this content
STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research ... |
| 09.11.2022 | Oncopeptides publishes Q3 report 2022 | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quart... |
| 09.11.2022 | Oncopeptides announces the market potential for Pepaxti in Europe | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential... |
| 09.11.2022 | Oncopeptides announces the market potential for Pepaxti in Europe | Oncopeptides announces the market potential for Pepaxti in Europe
Wed, Nov 09, 2022 07:57 CET Report this content
STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve... |
| 09.11.2022 | Oncopeptides publishes Q3 report 2022 | Oncopeptides publishes Q3 report 2022
Wed, Nov 09, 2022 08:00 CET Report this content
STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for dif... |
| 31.10.2022 | Number of shares and votes in Oncopeptides | Number of shares and votes in Oncopeptides
Mon, Oct 31, 2022 08:00 CET Report this content
STOCKHOLM — October 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies fo... |
| 27.10.2022 | Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen | STOCKHOLM — October 26, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces data from the phase 3 LIGHTHOU... |
| 22.10.2022 | Issue and re-purchase of class C shares for shareholder program and incentive program | STOCKHOLM — October 20, 2022 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has... |
| 20.10.2022 | Issue and re-purchase of class C shares for shareholder program and incentive program | Issue and re-purchase of class C shares for shareholder program and incentive program
Thu, Oct 20, 2022 18:15 CET Report this content
STOCKHOLM — October 20, 2022 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (... |
| 04.10.2022 | Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market | STOCKHOLM — October 3, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted ... |
| 23.09.2022 | Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC | STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Oncologic Drugs Adv... |
| 21.09.2022 | Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published | STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Ad... |
| 20.09.2022 | Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published | Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published
Tue, Sep 20, 2022 15:45 CET Report this content
STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on r... |
| 08.09.2022 | Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma | STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company has received... |
| 07.09.2022 | Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma | Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma
Wed, Sep 07, 2022 17:10 CET Report this content
STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on... |
| 30.08.2022 | Extraordinary General Meeting in Oncopeptides AB (publ) | Extraordinary General Meeting in Oncopeptides AB (publ)
Tue, Aug 30, 2022 18:00 CET Report this content
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptide... |
| 19.08.2022 | European Commission approves Oncopeptides’ Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | STOCKHOLM — August 18, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the European Commission ha... |
| 18.08.2022 | European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma
Thu, Aug 18, 2022 13:00 CET Report this content
STOCKHOLM — August 18, 2022 — Oncopeptides AB (publ) (Nasdaq Stockhol... |
| 11.08.2022 | Oncopeptides publishes Q2 report 2022 | STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quart... |
| 11.08.2022 | Oncopeptides publishes Q2 report 2022 | Oncopeptides publishes Q2 report 2022
Thu, Aug 11, 2022 08:00 CET Report this content
STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for diff... |
| 29.07.2022 | Number of shares and votes in Oncopeptides | Number of shares and votes in Oncopeptides
Fri, Jul 29, 2022 08:00 CET Report this content
Stockholm, Sweden — July 29, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapi... |
| 20.07.2022 | FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto | FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto
Wed, Jul 20, 2022 15:25 CET Report this content
STOCKHOLM — July 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO)... |
| 18.07.2022 | Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million) | Read more: https://www.oncopeptides.com/en/media/press-releases
|
| 28.06.2022 | Bulletin from the Annual General Meeting in Oncopeptides AB (publ) | Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Tue, Jun 28, 2022 14:00 CET Report this content
Stockholm, Sweden – June 28, 2022 – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Tuesday, 28 June ... |
| 23.06.2022 | CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma | CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma
Thu, Jun 23, 2022 17:55 CET Report this content
STOCKHOLM — June 23, 2022 — Oncopeptides AB (... |
| 25.05.2022 | Annual General Meeting in Oncopeptides AB (publ) | Annual General Meeting in Oncopeptides AB (publ)
Wed, May 25, 2022 15:15 CET Report this content
STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stoc... |
| 04.05.2022 | Oncopeptides publishes Q1 report 2022 | Oncopeptides publishes Q1 report 2022
Wed, May 04, 2022 08:00 CET Report this content
STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficul... |
| 27.04.2022 | Invitation to presentation of Q1 report | Invitation to presentation of Q1 report
Wed, Apr 27, 2022 15:00 CET Report this content
STOCKHOLM — April 27, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for dif... |
| 21.04.2022 | Oncopeptides publishes the 2021 Annual Report | Oncopeptides publishes the 2021 Annual Report
Thu, Apr 21, 2022 10:00 CET Report this content
STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies f... |
| 31.03.2022 | Number of shares and votes in Oncopeptides | Number of shares and votes in Oncopeptides
Thu, Mar 31, 2022 08:00 CET Report this content
STOCKHOLM — March 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for ... |
| 17.02.2022 | Oncopeptides publishes year-end report 2021 | STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021.
Financi... |
| 17.02.2022 | Oncopeptides publishes year-end report 2021 | Oncopeptides publishes year-end report 2021
Thu, Feb 17, 2022 08:00 CET Report this content
STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for diffi... |
| 14.02.2022 | Invitation to presentation of 2021 year-end results | Invitation to presentation of 2021 year-end results
Mon, Feb 14, 2022 18:45 CET Report this content
STOCKHOLM — February 14, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies f... |
| 21.01.2022 | Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time | Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time Fri, Jan 21, 2022 21:20 CET
STOCKHOLM — January 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focus... |
| 13.01.2022 | Oncopeptides phase 3 OCEAN study published in the Lancet Haematology | Oncopeptides phase 3 OCEAN study published in the Lancet Haematology Thu, Jan 13, 2022 08:00 CET
STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therap... |
| 12.01.2022 | Webcast for presentation of OCEAN data presented at IMW | Oncopeptides will present data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media are invited to participate in a webcast including a Q&A on September 12 at 16... |
| 05.01.2022 | Oncopeptides announces year-end cash 2021 | Oncopeptides announces year-end cash 2021 Wed, Jan 05, 2022 08:00 CET
STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat h... |
| 10.12.2021 | Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH | Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH Fri, Dec 10, 2021 08:00 CET
STOCKHOLM — December 10, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on rese... |
| 24.11.2021 | Oncopeptides publishes Q3 2021 report | Oncopeptides publishes Q3 2021 report Wed, Nov 24, 2021 08:00 CET
Back to the future
STOCKHOLM — November 24, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for diffi... |
| 19.11.2021 | Invitation to presentation of the Q3 2021 results | Invitation to presentation of the Q3 2021 results Fri, Nov 19, 2021 15:00 CET
STOCKHOLM — November 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to... |
| 15.11.2021 | Jakob Lindberg appointed CEO of Oncopeptides | Jakob Lindberg appointed CEO of Oncopeptides Mon, Nov 15, 2021 08:30 CET
STOCKHOLM — November 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-tr... |
| 12.11.2021 | Oncopeptides has announced the Nomination Committee | Oncopeptides has announced the Nomination Committee Fri, Nov 12, 2021 08:45 CET
STOCKHOLM — November 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in ... |
| 04.11.2021 | Oncopeptides focuses clinical development efforts to increase cash runway | Oncopeptides focuses clinical development efforts to increase cash runway Thu, Nov 04, 2021 17:35 CET
STOCKHOLM — November 4, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of the... |
| 01.11.2021 | Oncopeptides appoints Annika Muskantor as interim CFO | Oncopeptides appoints Annika Muskantor as interim CFO Mon, Nov 01, 2021 17:30 CET
STOCKHOLM — November 1, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult... |
| 22.10.2021 | Oncopeptides : withdraws Pepaxto® in US, scale down organization and focus on R&D | October 22, 2021
Regulatory
STOCKHOLM - October 22, 2021 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that... |
| 22.10.2021 | Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D | Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D Fri, Oct 22, 2021 14:55 CET
STOCKHOLM — October 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the develo... |
| 15.10.2021 | Oncopeptides’ CFO Anders Martin-Löf will leave the company | Oncopeptides’ CFO Anders Martin-Löf will leave the company Fri, Oct 15, 2021 17:35 CET
STOCKHOLM — October 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for diff... |
| 15.10.2021 | Oncopeptides' CFO Anders Martin-Löf will leave the company | STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that CFO Anders Martin... |
| 11.09.2021 | Oncopeptides presents phase 3 OCEAN study results at the IMW meeting | STOCKHOLM, Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today presents data from the phase 3 ... |
| 11.09.2021 | Oncopeptides presents phase 3 OCEAN study results at the IMW meeting | Oncopeptides presents phase 3 OCEAN study results at the IMW meeting Sat, Sep 11, 2021 10:15 CET
STOCKHOLM — September 11, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therap... |
| 09.09.2021 | Invitation to webcast for presentation of OCEAN data presented at IMW | Invitation to webcast for presentation of OCEAN data presented at IMW Thu, Sep 09, 2021 16:49 CET
STOCKHOLM — September 9, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therap... |
| 02.09.2021 | Regulatory update from US Food and Drug Administration | Regulatory update from US Food and Drug Administration Thu, Sep 02, 2021 17:06 CET
STOCKHOLM — September 2, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficu... |
| 27.08.2021 | Oncopeptides presents new data from OCEAN and PORT study - abstracts online | Oncopeptides presents new data from OCEAN and PORT study - abstracts online Fri, Aug 27, 2021 19:30 CET
STOCKHOLM — August 27, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of th... |
| 19.08.2021 | Oncopeptides publishes report for Q2 2021 | Oncopeptides publishes report for Q2 2021 Thu, Aug 19, 2021 07:00 CET
Launch dynamics encouraging, but US regulatory situation challenging
STOCKHOLM — August 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech compa... |
| 19.08.2021 | Philip Morris nabs over 20% of Vectura's shares; Oncopeptides drug may be headed for adcomm, CEO says | About a week after Vectura’s board of directors said they would unanimously back a Philip Morris takeover, the tobacco giant now has control of more than a fifth of the respiratory drugmaker’s shares.
Shareholders with 2... |
| 19.08.2021 | Oncopeptides : Financial Reporting Document | INTERIM REPORT
Q2 2021
Launch dynamics encouraging, but US regulatory situation challenging
Significant events
APRIL-JUNE
• Topline results from the phase 3 OCEAN
study were announced in May
• An application for conditional marketing
author... |
| 16.08.2021 | Oncopeptides' PEPAXTO® Receives a Permanent J-Code, Clarifying Reimbursement Processes in Hospital Outpatient and Physician Office Settings of Care | BOSTON, Aug. 16, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Centers for Medi... |
| 12.08.2021 | Invitation to presentation of the Q2 2021 results | Invitation to presentation of the Q2 2021 results Thu, Aug 12, 2021 13:00 CET
STOCKHOLM — August 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-t... |
| 28.07.2021 | Regulatory update from US Food and Drug Administration | Regulatory update from US Food and Drug Administration Wed, Jul 28, 2021 16:30 CET
STOCKHOLM — July 28, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-t... |
| 13.07.2021 | Oncopeptides' PEPAXTO ® Receives a Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care | BOSTON, July 13, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Centers for Medi... |
| 08.07.2021 | Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis | BOSTON, July 8, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces updated results and safety... |
| 26.05.2021 | Bulletin from the Annual General Meeting in Oncopeptides AB (publ) | Bulletin from the Annual General Meeting in Oncopeptides AB (publ) Wed, May 26, 2021 15:00 CET
Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Wednesday, 26 May 2021. At the Annual General Meeting... |
| 26.05.2021 | Oncopeptides : Financial Reporting Document | INTERIM REPORT
Q1 2021
A strong start for PEPAXTO in the US
Significant events
JANUARY-MARCH
PEPAXTO® was granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma on 26 Februar... |
| 26.05.2021 | ONCOPEPTIDES AB (PUBL)
Oncopeptides : Financial Reporting Document | INTERIM REPORT
Q1 2021
A strong start for PEPAXTO in the US
Significant events
JANUARY-MARCH
PEPAXTO® was granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma on 26 Februar... |
| 20.05.2021 | Invitation to presentation of the Q1 2021 results | Invitation to presentation of the Q1 2021 results Thu, May 20, 2021 08:30 CET
STOCKHOLM — May 20, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-trea... |
| 19.05.2021 | Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology | Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology Wed, May 19, 2021 23:00 CET
STOCKHOLM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused... |
| 05.05.2021 | Oncopeptides : Financial Reporting Document | ANNUAL REPORT 2020
Bringing HOPE through science
Content
This is Oncopeptides p.1 Remuneration Report p.41
2020 in brief p.2 Directors' Report p.43
Letter from the CEO p.4 Corporate Governance Oncopeptides 20 Years p.6 Report p.48
Consolida... |
| 05.05.2021 | ONCOPEPTIDES AB (PUBL)
Oncopeptides : completes patient enrollment in phase 2 PORT study | STOCKHOLM -- May 5, 2021 -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed pati... |
| 31.03.2021 | Number of shares and votes in Oncopeptides | Number of shares and votes in Oncopeptides Wed, Mar 31, 2021 08:00 CET
Stockholm — March 31, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise... |
| - | Oncopeptides announces year-end cash 2021 | STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces a financial update after the re... |
| - | Oncopeptides strengthens its organization by appointing Karolina Vilval as General Counsel | For more information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: *protected email*
Cell phone: +46 70 853 72 92
This information was submitted for publication at 08.00 CET March 2, 2020.
About Oncopeptides
Oncopeptide... |
| - | Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021 | A strong start for PEPAXTO in the US
STOCKHOLM — May 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today publ... |
| - | Oncopeptides to Apply for Accelerated Approval in the US | During the spring, Oncopeptides has been engaged in dialogue with the FDA to explore whether melflufen could be eligible for accelerated approval based on the promising data generated in the ongoing phase 2 HORIZON clinical trial. The targe... |
| - | Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO | Marty J Duvall brings extensive global commercialization skills from executive leadership roles in pharma and biotech including unique experience from the oncology and hematology space. Most recently as the CEO of Tocagen Inc.
“The submiss... |
